Heron Therapeutics, Inc.

HRTX

US4277461020

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
2.81 ^USD	-0.18%		-2.09%	+65.29%

05-07	Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

July 24, 2023 at 09:13 am

Heron Therapeutics, Inc. announced resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company, effective July 20, 2023.

Latest news about Heron Therapeutics, Inc.

Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	04-23	MT
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	03-21	CI
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	03-13	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	03-13	MT
Heron Therapeutics Shares Soar After Q4 Results Beat	03-13	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	03-13	MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	03-12	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	03-12	CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	01-24	DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	01-24	MT
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	01-23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	01-08	MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	01-08	MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	01-07	CI
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023	12-21	CI
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing	11-17	MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating	11-15	MT
Transcript : Heron Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q3 Revenue $31.4M, vs. Street Est of $31.8M	11-14	MT
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024	11-14	CI

Chart Heron Therapeutics, Inc.

Duration

Period

More charts

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Sector

Biotechnology & Medical Research

Calendar

09:30am - Investor Day

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Heron Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.81 USD

Average target price

6.75 USD

Spread / Average Target

+140.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HERON THERAPEUTICS, INC.	+65.29%	423M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+48.83%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research